Journal of Breast Cancer

Papers
(The TQCC of Journal of Breast Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Income Disparity in Breast Cancer Incidence and Stage at Presentation: A National Population Study of South Korea50
Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories41
The Significance of p-AKT1 as a Prognostic Marker and Therapeutic Target in Patients With Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Positive Early Breast Cancer29
Utilizing miR-34a-Loaded HER2-Targeting Exosomes to Improve Breast Cancer Treatment: Insights From an Animal Model22
Downstream Neighbor of Son Overexpression is Associated With Breast Cancer Progression and a Poor Prognosis20
Breast Cancer Statistics in Korea, 202116
Surgical Strategies for Partial Breast Reconstruction in Medial-Located Breast Cancer: A 12-Year Experience13
Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-0113
Canine as a Comparative and Translational Model for Human Mammary Tumor12
Prevalence of Programmed Death-Ligand 1 Positivity Using SP142 in Patients With Advanced Stage Triple-Negative Breast Cancer in Malaysia: A Cross-Sectional Study11
The Incidence of Occult Malignancy in Contralateral Risk Reducing Mastectomy Among Affected Breast Cancer Gene Mutation Carriers in South Korea10
Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data9
Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice9
Racial/Ethnic Differences in Pathologic Complete Response to Neoadjuvant Chemotherapy and Survival Among Early-Stage, Erb-B2 Receptor Tyrosine Kinase 2-Low Breast Cancer Patients9
The Usefulness of Ultrasound Surveillance for Axillary Recurrence in Women With Personal History of Breast Cancer9
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly9
The Radiological Response Rate Pattern Is Associated With Recurrence Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy9
Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy8
Intensive Surveillance for Women With Breast Cancer: A Multicenter Retrospective Study in Korea8
A Radiation Induced Low-Grade Myofibroblastic Sarcoma in the Retropectoral Area After Breast Conserving Surgery: A Case Report8
The Cancer/Testis Antigen CT45A1 Promotes Transcription of Oncogenic Sulfatase-2 Gene in Breast Cancer Cells and Is Sensible Targets for Cancer Therapy7
Atypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade On Surgical Excision6
Neoadjuvant Chemotherapy and Neoadjuvant Chemotherapy With Immunotherapy Result in Different Tumor Shrinkage Patterns in Triple-Negative Breast Cancer6
Prognostic Implication of Focal Breast Edema on Preoperative Breast Magnetic Resonance Imaging in Breast Cancer Patients6
Multicentric Breast Cancer of the Axillary and Pectoral Breasts: A Case Report and Literature Review5
Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy5
Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis5
Trends and Perspectives in Oncoplastic Breast Surgery: Findings From a Web-Based Survey With the Korean Breast Cancer Society5
AURKA Gene Variants rs1047972, and rs8173 Are Associated With Breast Cancer5
Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells5
Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis4
Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions4
Redefining In-Breast Tumor Recurrence: Unveiling Metastatic Dynamics and Shifting the Focus to Overall Survival in Breast Cancer Surgery Assessment4
Recent Advances in Malignant Phyllodes Tumors of the Breast4
CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience4
Waiting Time for Breast Cancer Treatment in Korea: A Nationwide Cohort Study4
The 21-Gene Recurrence Score Assay Improved Multidisciplinary Treatment Compliance in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: An Analysis o4
Feasibility of Ultrasound-Guided Localization for Clipped Metastatic Axillary Lymph Nodes After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Pilot Study4
Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level3
Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society3
Letter to the Editor: “Risk of Lymphedema After Sentinel Node Biopsy in Patients With Breast Cancer”3
Life-Threatening Hematoma in an Elderly Breast Cancer Patient Undergoing Chemotherapy3
Neoadjuvant Chemotherapy and Neoadjuvant Chemotherapy With Immunotherapy Result in Different Tumor Shrinkage Patterns in Triple-Negative Breast Cancer3
Effect of Interval Between Neoadjuvant Chemotherapy and Surgery on Oncological Outcomes in Poor Responders With Locally Advanced Breast Cancer3
Assessment of Neoadjuvant Treatment Response Using Automated Breast Ultrasound in Breast Cancer3
Intrathecal Catheter for Chemotherapy in Leptomeningeal Carcinomatosis From HER2-Negative Metastatic Breast Cancer3
0.076847076416016